摘要
以新冠肺炎为代表的传染病对人类健康和经济发展造成重大威胁。疫情暴发时的应急科研攻关是开发抗击疫情有力武器的关键,而有机结合了平时研究和应急攻关为一体的传染病防控平台是抗击疫情的基础。新冠肺炎疫情暴发以来,高福院士团队基于长期的研究积累,利用平急一体传染病防控平台,在新冠病毒的基础研究和应用研究两方面取得了重要成果,鉴定出新冠病毒的受体,揭示了新冠病毒以及变异株的入侵机制,跨种传播能力,基于入侵机制的理论基础开发出国际上第一个获批临床使用的新冠病毒重组亚单位疫苗以及在美国等十余国紧急使用的新冠肺炎治疗性抗体药物,迅速开发靶向3CL蛋白酶药物以及靶向入侵的多肽抑制剂,为中国以及世界新冠肺炎疫情的防控做出了重大贡献。
Viral pandemics,such as coronavirus disease 2019(COVID-19),pose major threats to both human health and economies.Based on the accumulated knowledge from basic and applied research,specific antiviral countermeasures can be developed rapidly,providing a crucial platform for the control and prevention of infectious diseases during public health emergencies.Since the outbreak of COVID-19,its causative agent being quickly discovered as severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the research team led by George F.Gao,academician of the Chinese Academy of Sciences,has made a series of important contributions to both basic and applied research against this devastating pathogen.The group very quickly identified the virus receptor as human angiotensin-converting enzyme 2(hACE2).They showed the receptor-mediated virus entry and inter-species transmission of SARS-CoV-2 and its variants on a structural level.Based on knowledge gained from viral entry studies,they developed the world’s first COVID-19 recombinant protein subunit vaccine authorized for clinical use,therapeutic antibody drugs authorized under emergency use authorization(EUA)in the USA and over 10 other countries,as well as small molecule drugs targeting the 3 CL protease and peptide-based inhibitor.The work has made a significant contribution to the prevention and control of COVID-19 in China and globally.
作者
王奇慧
齐建勋
严景华
高福
Qihui Wang;Jianxun Qi;Jinghua Yan;George Fu Gao(CAS Key Laboratory of Pathogen Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences(CAS),Beijing 100101;University of ChineseAcademyof Sciences,Beijing 100049;National Natural Science Foundation of China,Beijing 100085)
出处
《中国科学基金》
CSSCI
CSCD
北大核心
2022年第4期603-609,共7页
Bulletin of National Natural Science Foundation of China
基金
国家自然科学基金优秀青年科学基金项目(81922044)、专项项目(82041047)、重大研究计划项目(92169208)和重点项目(81830050)的资助。
关键词
新冠病毒
亚单位疫苗
中和抗体
多肽药物
受体结合域
变异株
SARS-CoV-2
subunit vaccine
neutralizing antibody
polypeptide drug
receptor-binding domain
variant
